-
1
-
-
84961642643
-
The INNs and outs of antibody nonproprietary names
-
26716992
-
Jones TD, Carter PJ, Plückthun A, Vásquez M, Holgate RGE, Hötzel I, Popplewell AG, Parren PWHI, Enzelberger M, Rademaker HJ, et al. The INNs and outs of antibody nonproprietary names. MAbs 2016; 8:1-9; PMID:26716992; http://dx.doi.org/10.1080/19420862.2015.1114320
-
(2016)
MAbs
, vol.8
, pp. 1-9
-
-
Jones, T.D.1
Carter, P.J.2
Plückthun, A.3
Vásquez, M.4
Holgate, R.G.E.5
Hötzel, I.6
Popplewell, A.G.7
Parren, P.W.H.I.8
Enzelberger, M.9
Rademaker, H.J.10
-
2
-
-
84871612935
-
-
World Health Organization. General policies for monoclonal antibodies. 2009; http://www.who.int/medicines/services/inn/Generalpoliciesformonoclonalantibodies2009.pdf
-
(2009)
General policies for monoclonal antibodies
-
-
-
3
-
-
85008882142
-
-
Jallal B., Vaughan T., Osbur J., (eds), Wiley
-
Watier H, Reichert J. Evolution of antibody therapeutics (Chapter 2). In:Jallal B, Vaughan T, Osbur J, eds Protein Therapeutics. Wiley, 2016 in press
-
(2016)
Protein Therapeutics
-
-
Watier, H.1
Reichert, J.2
-
5
-
-
0033866627
-
Antibody humanization: a case of the “Emperor”s new clothes’?
-
Clark M. Antibody humanization:a case of the “Emperor”s new clothes’? Immunol Today 2000; 21:397–402; PMID:10916143; http://dx.doi.org/10.1016/S0167-5699(00)01680-7
-
(2000)
Immunol Today
, vol.21
, pp. 397-402
-
-
Clark, M.1
-
6
-
-
84918578141
-
The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region
-
PMID:25342759; annrheumdis-2014-206237
-
Van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 2015; 74:311–4; PMID:25342759; http://dx.doi.org/10.1136/ annrheumdis-2014-206237
-
(2015)
Ann Rheum Dis
, vol.74
, pp. 311-314
-
-
Schie, K.A.1
Hart, M.H.2
de Groot, E.R.3
Kruithof, S.4
Aarden, L.A.5
Wolbink, G.J.6
Rispens, T.7
-
7
-
-
84897869100
-
Immunogenicity of therapeutic proteins: influence of aggregation
-
23919460
-
Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins:influence of aggregation. J Immunotoxicol 2013; 11:99-109; PMID:23919460; http://dx.doi.org/10.3109/1547691X.2013.821564
-
(2013)
J Immunotoxicol
, vol.11
, pp. 99-109
-
-
Ratanji, K.D.1
Derrick, J.P.2
Dearman, R.J.3
Kimber, I.4
-
8
-
-
84962582891
-
Immunogenicity to Biotherapeutics - The role of anti-drug immune complexes
-
26870037
-
Krishna M, Nadler SG. Immunogenicity to Biotherapeutics - The role of anti-drug immune complexes. Front Immunol 2016; 7:21; PMID:26870037; http://dx.doi.org/10.3389/fimmu.2016.00021
-
(2016)
Front Immunol
, vol.7
, pp. 21
-
-
Krishna, M.1
Nadler, S.G.2
-
9
-
-
84941183781
-
Monoclonal antibodies in excess: A simple way to avoid immunogenicity in patients?
-
25930194
-
Chaigne B, Watier H. Monoclonal antibodies in excess:A simple way to avoid immunogenicity in patients? J Allergy Clin Immunol 2015; 136:814-6; PMID:25930194; http://dx.doi.org/10.1016/j.jaci.2015.03.013
-
(2015)
J Allergy Clin Immunol
, vol.136
, pp. 814-816
-
-
Chaigne, B.1
Watier, H.2
-
10
-
-
0035210960
-
Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies
-
11717196
-
Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species:implications for therapeutic antibodies. Int Immunol 2001; 13:1551-9; PMID:11717196; http://dx.doi.org/10.1093/intimm/13.12.1551
-
(2001)
Int Immunol
, vol.13
, pp. 1551-1559
-
-
Ober, R.J.1
Radu, C.G.2
Ghetie, V.3
Ward, E.S.4
-
11
-
-
35648978158
-
Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment
-
17624800
-
Magdelaine-Beuzelin C, Kaas Q, Wehbi V, Ohresser M, Jefferis R, Lefranc M-P, Watier H. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Crit Rev Oncol Hematol 2007; 64:210-25; PMID:17624800; http://dx.doi.org/10.1016/j.critrevonc.2007.04.011
-
(2007)
Crit Rev Oncol Hematol
, vol.64
, pp. 210-225
-
-
Magdelaine-Beuzelin, C.1
Kaas, Q.2
Wehbi, V.3
Ohresser, M.4
Jefferis, R.5
Lefranc, M.-P.6
Watier, H.7
-
12
-
-
73449109876
-
-
World Health Organization. WHO Drug Information 2009; 23:195-9. http://www.who.int/medicines/publications/druginformation/issues/DrugInfo09vol23-2.pdf
-
(2009)
WHO Drug Information
, vol.23
, pp. 195-199
-
-
-
17
-
-
84910053743
-
Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis
-
25058694
-
Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera A-P, Pisella P-J, Gueyffier F, Bejan-Angoulvant T. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies:systematic review and meta-analysis. JAMA Ophthalmol 2014; 132:1317-26; PMID:25058694; http://dx.doi.org/10.1001/jamaophthalmol.2014.2333
-
(2014)
JAMA Ophthalmol
, vol.132
, pp. 1317-1326
-
-
Thulliez, M.1
Angoulvant, D.2
Le Lez, M.L.3
Jonville-Bera, A.-P.4
Pisella, P.-J.5
Gueyffier, F.6
Bejan-Angoulvant, T.7
-
18
-
-
84903644131
-
MAbImprove: a French “Laboratoire d'excellence” (LabEx) dedicated to therapeutic antibodies
-
Pèlegrin A, Daguet A, Watier H. MAbImprove:a French “Laboratoire d'excellence” (LabEx) dedicated to therapeutic antibodies. MAbs 2014; 6:803-4; http://dx.doi.org/10.4161/mabs.29262
-
(2014)
MAbs
, vol.6
, pp. 803-804
-
-
Pèlegrin, A.1
Daguet, A.2
Watier, H.3
-
19
-
-
84899083197
-
Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells
-
24701371
-
Pandey JP, Namboodiri AM. Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells. Oncoimmunology 2014; 3:e27317; PMID:24701371; http://dx.doi.org/10.4161/onci.27317
-
(2014)
Oncoimmunology
, vol.3
, pp. e27317
-
-
Pandey, J.P.1
Namboodiri, A.M.2
-
20
-
-
84918825382
-
IgG Subclasses and Allotypes: From structure to effector functions
-
Vidarsson G, Dekkers G, Rispens T. IgG Subclasses and Allotypes:From structure to effector functions. Front Immunol 2014; 5:1-17; http://dx.doi.org/10.3389/fimmu.2014.00520
-
(2014)
Front Immunol
, vol.5
, pp. 1-17
-
-
Vidarsson, G.1
Dekkers, G.2
Rispens, T.3
-
21
-
-
84954165258
-
IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding
-
26685205
-
Ternant D, Arnoult C, Pugnière M, Dhommée C, Drocourt D, Perouzel E, Passot C, Baroukh N, Mulleman D, Tiraby G, et al. IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding. J Immunol 2016; 196:607-13; PMID:26685205; http://dx.doi.org/10.4049/jimmunol.1501780
-
(2016)
J Immunol
, vol.196
, pp. 607-613
-
-
Ternant, D.1
Arnoult, C.2
Pugnière, M.3
Dhommée, C.4
Drocourt, D.5
Perouzel, E.6
Passot, C.7
Baroukh, N.8
Mulleman, D.9
Tiraby, G.10
-
22
-
-
84455208902
-
Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential
-
22186895
-
Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, de Haas M, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun 2011; 2:599; PMID:22186895; http://dx.doi.org/10.1038/ncomms1608
-
(2011)
Nat Commun
, vol.2
, pp. 599
-
-
Stapleton, N.M.1
Andersen, J.T.2
Stemerding, A.M.3
Bjarnarson, S.P.4
Verheul, R.C.5
Gerritsen, J.6
Zhao, Y.7
Kleijer, M.8
Sandlie, I.9
de Haas, M.10
-
23
-
-
70349769842
-
Human immunoglobulin allotypes: possible implications for immunogenicity
-
20073133
-
Jefferis R, Lefranc M. Human immunoglobulin allotypes:possible implications for immunogenicity. MAbs 2009; 1:332-8; PMID:20073133; http://dx.doi.org/10.4161/mabs.1.4.9122
-
(2009)
MAbs
, vol.1
, pp. 332-338
-
-
Jefferis, R.1
Lefranc, M.2
-
25
-
-
85008898085
-
Modifications in the IgG4 Fc portion of therapeutics in patents: opportunities for a twisting IgG subclass
-
Pottier J, Watier H, Gouilleux-Gruart V. Modifications in the IgG4 Fc portion of therapeutics in patents:opportunities for a twisting IgG subclass. Submitted 2016
-
(2016)
Submitted
-
-
Pottier, J.1
Watier, H.2
Gouilleux-Gruart, V.3
-
26
-
-
84922189761
-
conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies
-
25500122
-
White AL, Chan HTC, French RR, Willoughby J, Mockridge CI, Roghanian A, Penfold CA, Booth SG, Dodhy A, Polak ME, et al. conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell 2015; 27:138-48; PMID:25500122; http://dx.doi.org/10.1016/j.ccell.2014.11.001
-
(2015)
Cancer Cell
, vol.27
, pp. 138-148
-
-
White, A.L.1
Chan, H.T.C.2
French, R.R.3
Willoughby, J.4
Mockridge, C.I.5
Roghanian, A.6
Penfold, C.A.7
Booth, S.G.8
Dodhy, A.9
Polak, M.E.10
-
27
-
-
47049114087
-
Structural and functional characterization of disulfide isoforms of the human IgG2 subclass
-
18339626
-
Dillon TM, Ricci MS, Vezina C, Flynn GC, Liu YD, Rehder DS, Plant M, Henkle B, Li Y, Deechongkit S, et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 2008; 283:16206-15; PMID:18339626; http://dx.doi.org/10.1074/jbc.M709988200
-
(2008)
J Biol Chem
, vol.283
, pp. 16206-16215
-
-
Dillon, T.M.1
Ricci, M.S.2
Vezina, C.3
Flynn, G.C.4
Liu, Y.D.5
Rehder, D.S.6
Plant, M.7
Henkle, B.8
Li, Y.9
Deechongkit, S.10
-
28
-
-
84926659212
-
Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions
-
25657648
-
Monnet C, Jorieux S, Urbain R, Fournier N, Bouayadi K, De Romeuf C, Behrens CK, Fontayne A, Mondon P. Selection of IgG variants with increased FcRn binding using random and directed mutagenesis:impact on effector functions. Front Immunol 2015; 6:1-14; PMID:25657648; http://dx.doi.org/10.3389/fimmu.2015.00039
-
(2015)
Front Immunol
, vol.6
, pp. 1-14
-
-
Monnet, C.1
Jorieux, S.2
Urbain, R.3
Fournier, N.4
Bouayadi, K.5
De Romeuf, C.6
Behrens, C.K.7
Fontayne, A.8
Mondon, P.9
-
29
-
-
84950124556
-
Prevention and management of obinutuzumab-associated toxicities: Australian experience
-
26681665
-
Snowden A, Hayden I, Dixon J, Gregory G. Prevention and management of obinutuzumab-associated toxicities:Australian experience. Int J Nurs Pract 2015; 21 Suppl 3:15-27; PMID:26681665; http://dx.doi.org/10.1111/ijn.12412
-
(2015)
Int J Nurs Pract
, vol.21
, pp. 15-27
-
-
Snowden, A.1
Hayden, I.2
Dixon, J.3
Gregory, G.4
-
30
-
-
84928210441
-
Ocular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14.18K322A
-
25818285
-
Tse BC, Navid F, Billups CA, O'Donnell T, Hoehn ME. Ocular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14.18K322A. J AAPOS 2015; 19:112-5; PMID:25818285; http://dx.doi.org/10.1016/j.jaapos.2014.11.005
-
(2015)
J AAPOS
, vol.19
, pp. 112-115
-
-
Tse, B.C.1
Navid, F.2
Billups, C.A.3
O'Donnell, T.4
Hoehn, M.E.5
-
31
-
-
0014513216
-
The covalent structure of an entire gamma G immunoglobulin molecule
-
5257969
-
Edelman GM, Cunningham BA, Gall WE, Gottlieb PD, Rutishauser U, Waxdal MJ. The covalent structure of an entire gamma G immunoglobulin molecule. Proc Natl Acad Sci U S A 1969; 63:78-85; PMID:5257969; http://dx.doi.org/10.1073/pnas.63.1.78
-
(1969)
Proc Natl Acad Sci U S A
, vol.63
, pp. 78-85
-
-
Edelman, G.M.1
Cunningham, B.A.2
Gall, W.E.3
Gottlieb, P.D.4
Rutishauser, U.5
Waxdal, M.J.6
-
32
-
-
85008885540
-
International Nonproprietary Names for Pharmaceutical Substances (INN): Recommended International Nonproprietary Names List 75
-
World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN):Recommended International Nonproprietary Names List 75. WHO Drug Inf 2016; 75:19; http://www.who.int/medicines/publications/druginformation/innlists/RL75.pdf?ua=1
-
(2016)
WHO Drug Inf
, vol.75
, pp. 19
-
-
-
33
-
-
0015402447
-
Localization of antibody-combining sites within the variable portions of heavy and light chains
-
4560694
-
Inbar D, Hochman J, Givol D. Localization of antibody-combining sites within the variable portions of heavy and light chains. Proc Natl Acad Sci U S A 1972; 69:2659-62; PMID:4560694; http://dx.doi.org/10.1073/pnas.69.9.2659
-
(1972)
Proc Natl Acad Sci U S A
, vol.69
, pp. 2659-2662
-
-
Inbar, D.1
Hochman, J.2
Givol, D.3
|